Oculis (OCS): Privosergtor’s Breakthrough Profile in Optic Neuritis Supports First-in-Class Upside and Buy Rating

LifeSci Capital analyst Patrick Dolezal has maintained their bullish stance on OCS stock, giving a Buy rating today.

Patrick Dolezal has given his Buy rating due to a combination of factors centered on the strength of privosergtor’s clinical and regulatory profile in optic neuritis. He highlights that the FDA’s Breakthrough Therapy Designation underscores both the seriousness of the disease and the compelling Phase 2 ACUITY data, where patients on privosergtor showed marked gains in visual function and structural preservation of the optic nerve versus standard IV steroid therapy. This designation not only validates the drug’s potential to outperform current care but also offers a faster and more interactive regulatory path, including options for rolling submissions and potentially accelerated approval. In addition, the launch of the pivotal PIONEER-1 trial signals that the program is transitioning into a late-stage value-creation phase.

Dolezal also emphasizes the attractive market opportunity arising from a rare, vision-threatening condition with no approved treatments, drawing a parallel to Tepezza’s success in thyroid eye disease as a first-mover therapy in a similar neuro‑ophthalmic setting. He argues that privosergtor could replicate a comparable first‑in‑class, category‑defining trajectory in optic neuritis, with the potential for substantial commercial upside. Expert feedback referenced in his work further supports this view, as key opinion leaders regarded the efficacy and anatomical outcomes in the ACUITY trial as unusually robust compared with other investigational approaches. Taken together with Oculis’s cash runway and advancing development plan, these elements underpin his conviction that the risk‑reward profile justifies a Buy recommendation on OCS.

According to TipRanks, Dolezal is a 4-star analyst with an average return of 17.6% and a 43.93% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Kodiak Sciences, and Oculis Holding.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target.